People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Talphera, Inc. | — | Pharmaceuticals | Series B | $97.4M | $74.2M | 2022 |
| Xenoport Inc | — | Pharmaceuticals | Series B | $20.0M | $680.1M | 2012 |
Vincent J. Angotti at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vincent J. Angotti on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Wan | 1 | 10 |
| Stephen Hoffman | 1 | 7 |
| John G. Freund | 1 | 6 |
| Guy Nohra | 1 | 5 |
| Howard Rosen | 1 | 5 |
| Mark Edwards | 1 | 4 |
| William J. Rieflin | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
| James Welch | 1 | 4 |
| James H. Welch | 1 | 3 |
| Marina Bozilenko | 1 | 3 |
| Richard King | 1 | 3 |
| Anil Dasu | 1 | 2 |
| Guy J. Nohra | 1 | 2 |
| Wendell J. Wierenga | 1 | 2 |
| Jeryl L. Hilleman | 1 | 2 |
| David R. Savello | 1 | 2 |
| RAFFI ASADORIAN | 1 | 2 |
| Guy B Nohra | 1 | 2 |
| Paul L. Berns | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.